Abstract
Mitomycin C at a dose of 20 mg/m2 i.v. every 6 weeks was administered to 15 evaluable patients with measurable advanced soft tissue sarcomas resistant to standard treatment. No response was observed. Disease stabilization occurred in 5 patients, with a median duration of 4 months. Toxicity was generally mild to moderate. On the basis of this study, mitomycin C, in the dosage and schedule used in the above study, cannot be recommended in the treatment of this disease.
| Original language | Italian |
|---|---|
| Pages (from-to) | 83-85 |
| Number of pages | 3 |
| Journal | Clinica Terapeutica |
| Volume | 115 |
| Issue number | 2 |
| Publication status | Published - 1985 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
MITOMICINA C NEL TRATTAMENTO DEI SARCOMI DEI TESSUTI MOLLI DELL'ADULTO IN FASE AVANZATA. / Di Lauro, L.; Balice, A.; Papaldo, P.; Lopez, M.
In: Clinica Terapeutica, Vol. 115, No. 2, 1985, p. 83-85.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - MITOMICINA C NEL TRATTAMENTO DEI SARCOMI DEI TESSUTI MOLLI DELL'ADULTO IN FASE AVANZATA
AU - Di Lauro, L.
AU - Balice, A.
AU - Papaldo, P.
AU - Lopez, M.
PY - 1985
Y1 - 1985
N2 - Mitomycin C at a dose of 20 mg/m2 i.v. every 6 weeks was administered to 15 evaluable patients with measurable advanced soft tissue sarcomas resistant to standard treatment. No response was observed. Disease stabilization occurred in 5 patients, with a median duration of 4 months. Toxicity was generally mild to moderate. On the basis of this study, mitomycin C, in the dosage and schedule used in the above study, cannot be recommended in the treatment of this disease.
AB - Mitomycin C at a dose of 20 mg/m2 i.v. every 6 weeks was administered to 15 evaluable patients with measurable advanced soft tissue sarcomas resistant to standard treatment. No response was observed. Disease stabilization occurred in 5 patients, with a median duration of 4 months. Toxicity was generally mild to moderate. On the basis of this study, mitomycin C, in the dosage and schedule used in the above study, cannot be recommended in the treatment of this disease.
UR - http://www.scopus.com/inward/record.url?scp=0022380137&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022380137&partnerID=8YFLogxK
M3 - Articolo
C2 - 3935361
AN - SCOPUS:0022380137
VL - 115
SP - 83
EP - 85
JO - Clinica Terapeutica
JF - Clinica Terapeutica
SN - 0009-9074
IS - 2
ER -